Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZBH
STRONG BUYAPPROVEZimmer Biomet Holdings, Inc. · Healthcare · United States · $17.7B · Avg Vol: $207M/d
Zimmer Biomet clears the calibrated bar. All three legs are above the floor (Q55 V62 M66) and an active buyback provides the required corroboration. Nothing adverse survives the evidence test: the only insider figure on file is selling that rounds to 0.00% of shares outstanding, which the framework treats as unusable rather than adverse, and there is no negative earnings revision. Orthopaedic implant demand is supported by demographics and by a procedure backlog that continues to work through.
COMPANY DESCRIPTION
Zimmer Biomet Holdings, Inc. is a global leader in musculoskeletal healthcare, specializing in the design, manufacture, and marketing of orthopedic reconstructive products, spine and dental solutions, and related surgical technologies. The company maintains a strong competitive position through its expansive product portfolio, deep relationships with surgeons and hospitals, and continuous R&D investment in innovative surgical solutions. Zimmer Biomet is a dominant force in the global orthopedic implant market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.9B | 7.4B | 7.7B | 8.2B | 5.9% | 8.4B | 8.5B | 8.8B | 3.6% |
| EPS | 1.10 | 4.91 | 4.45 | 3.56 | 47.9% | 3.80 | 3.68 | 3.91 | 4.8% |
| Shares | 209.0M | 205.6M | 199.1M | 195.5M | -6.5% | 193.5M | — | — | — |
| Debt | 5.7B | 5.8B | 6.2B | 7.5B | 9.7% | 7.6B | — | — | — |
| Equity | 12.0B | 12.5B | 12.5B | 12.7B | 1.8% | — | — | — | — |
| Op CF | 1.3B | 1.6B | 1.5B | 1.7B | 9.7% | 1.7B | — | — | — |
| Inv CF | -529.2M | -778.9M | -888.1M | -2.0B | — | — | — | — | — |
| Fin CF | -843.8M | -763.5M | -484.5M | 326.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZBH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZBH | Zimmer Biomet Holdings, Inc.(you) | $17.7B | 91 | STRONG BUY |
| GMED | Globus Medical, Inc. | $10.4B | 93 | STRONG BUY |
| STE | STERIS plc | $20.9B | 80 | STRONG BUY |
| DXCM | DexCom, Inc. | $27.6B | 82 | STRONG BUY |
| GEHC.MX | GE HealthCare Technologies Inc. | $27.5B | 68 | BUY |
| BIO-B | Bio-Rad Laboratories, Inc. | $8.3B | 72 | BUY |
| HAE | Haemonetics Corporation | $3.6B | 89 | STRONG BUY |
| EW | Edwards Lifesciences Corporation | $47.6B | 72 | BUY |
| PEN | Penumbra, Inc. | $12.5B | 54 | HOLD |
| BRKR | Bruker Corporation | $9.2B | 59 | HOLD |
Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.5%